Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15954333 | 1.00 | ESR1 (0.45) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL10098028 | 1.00 | ESR1 (0.45) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL30362809 | 1.00 | ESR1 (0.45) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL19655436 | 0.89 | ESR1 (0.47) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL26945956 | 0.89 | ESR1 (0.43) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL10074007 | 0.88 | ESR1 (0.47) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL15312100 | 0.88 | ESR1 (0.47) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL18898167 | 0.88 | ESR1 (0.47) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL30362852 | 0.88 | ESR1 (0.47) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL2719199 | 0.88 | ESR1 (0.47) | ESR1ESR2CYP3A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | Aardvark Therapeutic, Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| WO-2016126618-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2635121-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Marshall Edwards, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | ESR1 2467/4885ESR2 1403/4885CYP3A4 4003/4885 |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | CYP19A1, HSD17B11, BRCA1 | ESR1 71/4885ESR2 9/4885CYP3A4 983/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | ESR1 3784/4885ESR2 2187/4885CYP3A4 4039/4885 |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885CYP3A4 2283/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885CYP3A4 2283/4885 |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | ESR1 57/4885ESR2 22/4885CYP3A4 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.